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The utility of Positron Emission Tomography (PET) in the detection of cancer began with the
radiopharmaceutical 2-[18F]fluoro-2-deoxyglucose (FDG) used for measuring altered cellular
metabolism. Specific radioligands are being developed to allow non-invasive analysis of protein
expression to further characterize tumors. One protein that has been identified as a promising
target is the Peripheral Benzodiazepine Receptor (PBR). PBR expression is up-regulated in
several cancers, and in many there has been a correlation drawn between increased malignancy
and protein expression levels. Therefore, developing PET methodologies to apply for PBR
imaging could be an important step in understanding individual tumors as we move toward an
age of personalized medicine.

This dissertation investigates the potential utility of two

radioligands specific for PBR, and compares the radioligands to radiopharmaceuticals that map
metabolism (FDG) and proliferation (3’-[18F]fluoro-L-thymidine, FLT). The research has two
specific aims: 1) to compare PBR expression with measures of cellular proliferation and
aggression; 2) to directly compare radioligand localization in vivo to tumor sites in mouse
ii

xenograft model studies. In vitro cell studies indicate a correlation between PBR expression and
markers of aggression, but not proliferation. Using PET imaging and biodistribution, breast
cancer xenografts with a breadth of PBR expression showed no significant uptake of PBR specific
radioligands. However, radiopharmaceuticals targeting proliferation by metabolism and DNA
synthesis showed greater differences in uptake between cell lines. The data obtained from
these studies demonstrate a limitation to the translation of PBR imaging for personalized
medicine, because the ubiquitous expression of the protein throughout the body creates
challenges that will be difficult to overcome. Expression of PBR in non-target organs reduces the
quantity of radiopharmaceutical that is available for tumor uptake, and the extent of non-tumor
uptake of radiopharmaceuticals with affinity for PBR exceeds that of tumors. These results
suggest that non-invasive imaging techniques to assay tumor PBR expression in vivo have limited
potential for clinical applications.
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Chapter 1
Introduction
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Identification of Benzodiazepine Receptors
Benzodiazepines are a class of drugs widely utilized for their anxiolytic, sedative,
hypnotic and anticonvulsant effects.1, 2 Beginning in the 1970s, there have been investigations
aimed at better understanding the exact mechanisms by which these compounds mediate their
actions, initially focusing on identifying their specific binding site.3-7 Early data pointed to the
glycine receptors in studies with tritiated strychnine.3 However, γ-aminobutyric acid (GABA)
association was hypothesized as an alternative, and this theory was supported by further
studies.7, 8
In 1977, two groups simultaneously found a specific, discrete benzodiazepine binding
site using synaptosomal preparations of brain homogenates.5, 6, 9-11 Both groups reported results
of binding studies using [3H]diazepam (Valium®).5, 6 They first measured the displacement of
[3H]diazepam in rat brain homogenates using several benzodiazepines, representing both potent
and weak anxiolytic members of this class of compounds. They observed that there was a
positive correlation between the displacement and predictors of therapeutic benefit. In other
publications, Mohler et al. examined binding conditions10 and the specific uptake and
displacement in human brain homogenates.11 Braestrup and Squires followed up with a paper
that examined binding patterns and specificity, including peripheral tissues.9 They noted that
there was a fifteen-fold lower binding affinity in non-neuronal tissues, including kidney and liver,
compared to the brain. They also observed a difference in the cellular localization, showing
membrane binding in brain and mitochondrial binding in peripheral tissues. In displacement
studies of [3H]diazepam in homogenates with clonazepam (a potent anxiolytic drug) and Ro54864 (a benzodiazepine with no pharmacological effect), two pharmacologically distinct
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benzodiazepine receptors were characterized. These two receptor types are referred to as the
Central Benzodiazepine Receptors (CBR) and the Peripheral Benzodiazepine Receptors (PBR).
Benzodiazepine Receptor Pharmacology
CBRs and PBRs display distinct binding patterns.

When Braestrup and Squires9

performed binding displacement studies on brain homogenates using [3H]diazepam (Figure 1A),
clonazepam (Figure 1B) displayed potency, with an IC50 value of 5.0 nM, while Ro 5-4864 (Figure
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clonazepam

Cl

potency

was
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Cl
Clonazapam
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of 2.9 mM, 5.0 mM, and 7.9 mM,

Figure 1: Structures of benzodiazepines utilized by
Braestrup and Squires for receptor characterization.

respectively) and Ro 5-4864 was

Diazepam

much more potent (IC50 values of
4.7 nM, 4.1 nM, and 4.8 nM, respectively). Subsequently, Syapin and Skolnick utilized similar
methods to investigate the potential of cultured glial cells, the C6 cell line, for the study of
CBR.12 They found that these cultured cells of neural origin unexpectedly had binding properties
that mimicked kidney rather than cortex. In further investigations, PBR was found to be
expressed within the central nervous system (CNS), including on glial cells and in the olfactory
bulb. 13-17
Central Benzodiazepine Receptors
The identified relationship between the Central Benzodiazepine Receptor and the
GABAA receptor has been extensively explored.7, 18-25 To summarize, the GABAA receptor is a
3

ligand-gated ion channel and is composed of five subunits per channel to form an ion pore. CBR
is a component of the GABAA complex, which includes chloride channels.26 GABAA receptor
subunits are classified as α, β, γ, δ, ε, θ, and ρ. The pentamer is composed of at least one α, at
least one β, and at least one other subunit type. The α subunit is most influential for the
benzodiazepine binding site. There are six isoforms (denoted by numerical subscript) of the α
subunit, and it has been demonstrated that each isoform gives unique benzodiazepine
pharmacology.25, 27 Two subtypes of note are combinations of α1,β2, and γ2 and α2, β3, and γ2;
with the former the sedative and anticonvulsant effects are seen with benzodiazepine binding,
while the latter displays the anxiolytic effects.27
Peripheral Benzodiazepine Receptors
The peripheral benzodiazepine receptor has several alternative names in the literature.
These include subtle variations such as the peripheral benzodiazepine binding site or peripheraltype benzodiazepine receptor, and attempts to rename the protein like omega (ω) receptor,
mitochondrial DBI receptor (MDR) and most recently, the translocator protein (TSPO). These
latter names reflect on the evolution of our understanding concerning this protein.

For

instance, the suggestion for renaming the benzodiazepine receptors the omega receptors (1 and
2 for CBR subtypes, and 3 for PBR) came after it was determined that other classes of
compounds could bind at the site and the central nervous system contained both the GABAassociated CBR and PBR.28 TSPO was proposed in 2006 because investigations into the roles
played within the cell by PBR have yielded a list of direct and indirect involvements.29 This work
will refer to the protein by the historic name, PBR.

4

Ligands for PBR
O

The benzodiazepine Ro5-4864, utilized in the
characterization of the benzodiazepine binding sites,
was the first selective ligand.

N
N

The isoquinoline

carboxamide PK11195 (Figure 2), was developed and
compared both in vitro and in vivo.17,

30

(1-methylpropyl)-3-isoquinolinecarboxamide,
tritiated

Ro5-4864

and

Cl

Le Fur et al.

found that PK11195, 1-(2-chlorophenyl)-N-methyl-N-

displace

Me*

could

matched

the

Figure 2: Structure of PBR ligand
PK11195. The asterisk indicates the
site of radiolabel with tritium or
carbon-11.

distribution pattern. They went on to characterize the ligand interactions, suggesting that
PK11195 acts as an antagonist while Ro5-4864 is an agonist.31
PK11195 has emerged as the standard ligand for PBR. One important reason for this
was the species variations in Ro5-4864 affinity while PK11195 had similar values across
species.32-34 Both ligands displayed a high affinity for rodent PBR, with KD in the range of 15

nM.17 However, Ro 5-4864 has greater variation of affinity between species,33-36 rising to
micromolar levels in human and bovine tissues,32, 37 while the affinity of PK11195 remains
below 20 nM in all species tested.17, 32, 34, 36, 38
Reconstitution studies in bacteria suggested an explanation for this occurrence.
PK11195 binds only to an 18 kDa protein, referred to as the isoquinoline binding protein (IBP).
However, Ro5-4864 was suggested to require both the 18 kDa protein and a 32 kDa protein
(voltage dependent anion channel, VDAC) for binding. It was hypothesized that VDAC may have
greater species variation, and this would explain the reduced affinity in some species. A third
protein identified as a component in the multimer is the adenine nucleotide carrier (ANC) or
5

adenine nucleotide translocase (ANT), with a molecular weight of 30 kDa.39, 40 In 1997, though,
the necessity of VDAC was refuted.41 Therefore sequence differences in IBP between species
are now thought to explain the binding of Ro5-4864.42
Distribution and Roles of PBR

PBR is found in most tissues outside the CNS43, and in low levels within non-neural
tissues of the CNS.12, 44, 45 Organs of expression include, but are not limited to kidney, adrenal
and heart. Steroidogenic tissues have the highest expression levels.17, 43, 46 PBR is found on

macrophages and microglia.47
PBR is most commonly associated with the outer mitochondrial membrane48,
although it has also been isolated in the plasma membrane49, 50 and nucleus.51, 52 Figure 353
represents a simplified version of the complex as it is found in vivo. A variety of roles have
been identified for PBR, including involvement in cell proliferation,52, 54-58 cell respiration,59
calcium influx60 and steroid synthesis.61-63

Fig. 3. The PBR complex and its
protein components in the
mitochondrial membrane. Figure
reprinted with permission from
Moshe Gavish, PhD at the
Rappaport Institute, Isreal .

The 18 kDa isoquinoline binding protein has been further characterized. It has >80%
sequence homology between species and is 169 amino acids.64 The protein forms five alpha
helices and inserts with the C-terminus extending into the cytoplasm while the N-terminus is
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within the mitochondria.65 Rather than exist as a trimer, with one of each subunit (IBP, ANC,
VDAC), it has been suggested that multiple (2-6) IBP may be found together with ANC and
VDAC.66 It has been proposed that additional uncharacterized proteins associate to create

the complete receptor structure required for each role.64
PBR Expression in Cancer
Investigations on the importance of PBR expression in cancer initially focused on
cancers of the brain, in particular gliomas and astrocytomas. Several groups have shown
that PBR levels are elevated, with ratios of 3- to 20-fold higher expression in vitro for tumor
compared to normal brain tissue.37, 67-72
Peripheral benzodiazepine receptors have been shown to have elevated expression
in different types of cancers, including brain cancers37,

67-71, 73, 74

, colon75, breast51,

endometrial76, ovary77, prostate78 and liver79 cancers. It has been found that PBR expression
is higher in more aggressive tumor tissues (breast, colon and prostate) and breast tumor cell
lines compared to less aggressive phenotypes.51,

80

Additionally, when low and high PBR

expressing MDA-MB-231 (breast cancer) lines were compared, it was found that only the high
PBR cells were able to grow and establish tumors in SCID mice.81, 82

In a study performed with colon cancer patients, it was found that stage III and IV
tumors display similar, increased expression of PBR levels.83 When investigators compared
patient prognoses to expression levels, they found that PBR expression was an important
factor in patient survival. Followed out to approximately 105 months, patients with high
PBR expressing tumors had a 20% overall survival rate, compared to 80% when PBR
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expression was low. Investigators have suggested that PBR overexpression contributes to
tumor growth, though the specific role of PBR in cancer is not yet well understood.
An Overview of Imaging Today
Nuclear medicine techniques have developed to become cornerstones of modern
medicine, but are still undergoing rapid advancement. Imaging can be utilized to gather data on
physical structures of the body (anatomy) or measure cellular activities (physiology.) Computed
tomography (CT) and magnetic resonance imaging (MRI) are utilized for visualizing anatomy. CT
has improved in resolution and reduced acquisition time by expanding the detection field, and
current clinical instruments have resolution capacities below 0.5 mm.84 Similarly, MRI can
provide high-resolution anatomical data.85

Magnetic resonance spectroscopy (MRS) and

functional MRI (fMRI) are being evaluated for their use in providing physiological data. Positron
emission tomography (PET) and single photon emission computed tomography (SPECT) are
widely used for a noninvasive analysis of physiology. SPECT isotopes typically are longer lived
allowing for equilibrium at receptors.

However SPECT instrumentation has less spatial

resolution when compared to PET. The most commonly used PET isotopes require on-site
production facilities. However, PET displays two very important properties: detection with PET
is more sensitive and the resolution is better.85-87 PET is considered to be the method of choice
for functional imaging.
Today’s clinical instruments are dual technology to incorporate the anatomical data with
the functional data, such as PET/CT. By combining the information, the physiological data can
be overlaid with the anatomy.88

Utilizing these techniques, doctors are able to perform

noninvasive tests toward the goal of characterizing a patient’s disease.

8

Positron Emission Tomography
For PET studies, patients are injected with a radiopharmaceutical and imaged. The
mechanism behind PET is outlined in Figure 4. The unstable nucleus of the radionuclide emits a

positron.. This positron will travel a short, characteristic distance (positron range) within the
tissue before an annihilation event occurs by a collision with an electron. Annihilation events
result in the production of two 511 keV gamma rays approximately 180 degrees apart. The
patient is surrounded by a ring of coincidence detectors, discrete scintillation crystals that
absorb the photons and emit light. A line of response (LOR) forms when the two gamma rays
are detected at the scintillation crystal within tthe
he narrow timeframe set as the window of
coincidence, usually nanoseconds. The light emitted by the scintillation crystals is detected by
the photomultiplier tubes (PMT) which converts light to photoelectrons, and amplifies the
electric signal (Figure 5). Signal data is collected by computer and analyzed by algorithms to
generate an image and capture the information from the study.

9

Figure 5: Images of a crystal array, demonstrating the arrangement of crystals. Crystals detect
photons, resulting in light
ht emissions. This light is transmitted into the photomultiplier tubes
(PMT) that converts the light into photoelectrons and amplify the signal. Images were
provided by Richard LaForest, PhD and Yuan Chan Tai, PhD at Washington University.
The first majorr change in PET instrumentation was in the advancements in scintillation
crystals. Early instruments had sodium iodide (NaI
(NaI-TI).
TI). These did not work well as the efficiency
of detection for the 511 keV annihilation photons was poor. Sensitivity is measured
measure as the
percentage of the gamma rays that are actually detected. Second and third generation crystals
generated from new scintillation materials have been utilized to better stop the gamma rays,
improving the sensitivity.88 This is an important improvement
ent because high quality images
requires sufficient signal detection for reconstruction, yet this must be balanced with minimal
injected dose and absorbed radiation dose by the subject. Sensitivity and spatial resolution
require optimization in scanner de
design.
sign. Sensitivity is maximized by surface area for detection.
However the spatial resolution is improved by increasing the number of crystals85, therefore
reducing the surface area. Such refinements in instrumentation continue as the clinical and
research
ch applications for PET increase.

10

Small Animal PET
Small animal PET followed instrumentation for human imaging, but it has seen dramatic
improvements. It provides an important tool for the development of radiotracers for translation
into humans and also an opportunity to analyze animal models of human diseases. The spatial
resolution of human scanners was insufficient for such applications. The smaller bodies and
organs of the rodents being imaged required an increase in spatial resolution, without sacrificing
the sensitivity.89 Today there are scanners available with 1 mm resolution while retaining
detector sensitivity.90
Radionuclides
A radiopharmaceutical is a compound given in trace quantities that has been labeled
with a radionuclide. There are several radionuclides to choose for labeling tracers for PET. They
fall into two broad categories involving covalent or ionic bonds. In the first category, such as
carbon-11 and fluorine-18, the radionuclide is attached directly onto the substrate during the
radiosynthesis. The other category of creating a radiopharmaceutical is utilized for metals such
as copper-64 or gallium-68. Protein targeting moieties are coupled through a linker to a
chelator prior to radiosynthesis. Metallic radionuclide is added, and by chelation the activity is
incorporated into the molecule.
Today, the two most commonly used PET nuclides are fluorine-18 and carbon-11. Both
are produced on a cyclotron and require on-site production. Carbon-11 has a half-life of 20.4
minutes, decays with emission of a positron (100%), and has maximum positron energy of 960
kEV.91

It is produced by the

14

N(p,α)11C reaction on mixed target of N2/0.5 % O2.

The

bombardment generates [11C]CO2, which can be reduced to [11C]CH4 and iodinated for
incorporation onto compounds as [11C]CH3I. At Washington University School of Medicine, the
11

reduction is carried out in the GE PETtrace® MeI Microlab. [11C]CO2 is first reduced to [11C]CH4
and run over an iodine column to make the final product, [11C]CH3I, that is transferred to
reaction vessels for direct incorporation onto the substrate. Fluorine-18 has a half-life of 109.7
minutes, decays by emission of a positron (100%) with maximum positron energy of 634 keV. It
can be produced by the 18O(p,n)18F reaction on isotopically enriched water ([18O ]H2O).91
Fluorine-18 has properties that make it convenient to use in imaging; although both
radionuclides can be used to provide useful clinical information. The longer half-life of fluorine18 gives it a few advantages. First, radiosyntheses with fluorine-18 can be several hours long if
there are reaction steps that make this necessary. When using carbon-11, syntheses must be
constrained so that the isotope is incorporated and product is purified in one hour (three halflives). Second, the use of a fluorinated radiotracer allows a longer imaging window and may be
better for reaching equilibrium or maximizing target localization, depending on the tracer.
Imaging sessions with fluorine-18 can extend pass two hours while carbon-11 should not be
imaged past 90 minutes post-injection. However, the short half-life of [11C]methylated tracers
means that these can be used for imaging the subject successively on the same day.
Applying PET
PET provides a powerful tool for the detection and characterization of cancer. The noninvasive technique allows for ease in repetitive testing, for example as tumor response is
monitored during therapy.92, 93 A major advantage to imaging a tumor to supplement a biopsy is
the limitation of biopsy from the small sample size excised. If heterogeneity is present within a
tumor, imaging provides a quantifiable analysis of the whole tumor.87 To this end, many
approaches can be taken. Tracers can be designed as analogs to target a metabolic pathway, to
mimic ligands and bind specific proteins, or as markers of an indicative cellular process, such as
12

DNA or protein synthesis.88 The potential for ligand-targeted radiopharmaceuticals is especially
broad. Proteins involved in angiogenesis94, hypoxia94, proliferation95, and metastatic potential96
are among those under investigation as cancer imaging agents. These target methods have
been employed in oncological imaging with PET.
The most widely used tracer is [18F]FDG, 2-[18F]fluoro-2-deoxyglucose (Figure 6).
[18F]FDG is a fluorinated analog to glucose, and is a

HOH2C
O

measure of glucose utilization. Tumor metabolism of HO
HO

glucose is altered from normal cells as tumor cells are
18

OH

F

rapidly dividing and therefore consuming more
18

nutrients. [ F]FDG is phosphorylated by hexokinase

Figure 6: [18F]FDG, 2-[18F]fluoro-2deoxyglucose

and trapped within the cell.97
A second option for imaging tumors is to target DNA synthesis. This can be done by
O

identifying cellular elements important in synthesis of the building
blocks, nucleotides.

Thymidine Kinase 1 (TK1) emerged as a

promising target based on two ideas.

NH

Thymidine is the only

nucleotide that is exclusive to DNA, and TK1 has been shown to be

N

O

HO
O

98

upregulated in cancer tissues.

Thymidine has been labeled with
18

F

both carbon-11 and fluorine-18 as a substrate for TK1
imaging.99, 100 When labeled with carbon-11, metabolism was
found to be rapid.101,

102

Figure 7: [18F]FLT, 3’-deoxy-3’[18F]fluorothymidine

When labeled as an analog with fluorine-18 as 3’-deoxy-3’-

[18F]fluorothymidine (FLT) (Figure 7) however, the PET tracer displayed more promising
characteristics, and has become the major means for imaging DNA synthesis.99
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Glucose metabolism and DNA synthesis have been developed for PET imaging and
provided a great deal of insight. However, problems have been observed.88, 97 For one, [18F]FDG
also localizes to sites of inflammation.103 Additionally, the relatively high glucose consumption
of the brain makes tumor localization and tumor-to-background signal poor. Both [18F]FDG and
[18F]FLT also localize to non-tumor sites in the body that have cells that are dividing rapidly, such
as the gastrointestinal tract.
Ligand-specific protein interactions provide a third option for looking at proliferation.
Several proteins have been identified whose increased expression correlates with tumor
proliferation. As noted earlier, PBR is one such protein. An advantage to this approach is the
potential of specific radiotracer uptake.104
Many factors must be considered in radiopharmaceutical design.105 These compounds
must possess adequate localization properties to ensure that in vivo distribution mimics in vitro
uptake. Metabolic stability is very important so that the tracer is delivered intact to the cells.
Secondly, the radiotracer must be able to cross the cell membrane if the target protein is
intracellular. If the target is in the brain, the radiopharmaceutical must be lipophilic enough to
cross the blood-brain barrier. Ligand-specific interactions present additional challenges for
optimal target to non-target localization. The radioligand should have nanomolar affinity for the
receptor, and to avoid receptor saturation and distribution to non-target tissues, the specific
activity of the radiotracer should be as high as possible.
Peripheral Benzodiazepine Receptor Specific Ligands
Brain imaging has been the focus of PBR ligand development. Bergstrom et al labeled
Ro5-4864 with carbon-11 and imaged patients with gliomas. As it had been shown that this
ligand had reduced affinity in human tissues32, it is not surprising that they found no uptake
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above background.106 PK11195, however, gave different results. When tritiated and analyzed
by in vivo autoradiography, PK11195 localized to the tumor.74, 107 Carbon-11 labeled PK11195
was then considered as a glioma imaging agent in two human studies.108, 109 The investigators
found a two-fold increase in tumor uptake compared to normal brain tissue. Pappata et al
additionally demonstrated that the uptake was specific by giving a patient a blocking dose of
PK11195 in a second imaging session. Tumor uptake was reduced and tracer was more evenly
distributed, as one would expect when sites for selective uptake are blocked.109
In the mid-1990’s a series of studies were published that brought attention to the
potential utility of PBR. The first was a comparison study that measured [18F]FDG uptake in vivo
by PET and [3H]PK11195 in vitro on excised tissue samples by autoradiography. They observed a
different behavior in treated versus untreated tumor. If the patient had undergone therapy,
there was no correlation between the glucose and PBR specific ligand.

However, when

untreated, glucose uptake correlated with PBR ligand binding.110 In another experiment, an in
vitro binding study was performed on patient samples representing a range of glioma grade, and
binding of [3H]PK11195 was found to be elevated in high grade tumors.71, 111 Investigations of
neuroinflammatory diseases such as Alzheimer’s Disease112 and Multiple Sclerosis113 were also
performed with PET and [11C]PK11195. Distribution was heterogeneous and indicated that the
tracer was localizing to sites of inflammation within the brain. These data encouraged the
development of novel ligands for PBR in nuclear imaging.
In the last decade several new compounds have been synthesized.114, 115 PK11195 and
Ro5-4864 have been used as a lead compounds in the synthesis of these derivatives. Preclinical
evaluations of these ligands continue since PBR is a protein marker and imaging target in cancer
and inflammation. To date, PK11195 remains the standard to which all others are compared.116
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The class of ligands phenoxyphenyl-acetamide derivatives appears to hold great
potential.

In 1999, Taisho Pharmaceutical Company published a report identifying ligand

DAA1106, N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide, which displayed
selectivity and increased affinity for PBR.117

They found that the compound inhibited

[3H]PK11195 and [3H]Ro5-4864 binding at PBR with concentrations of less than one nanomolar,
while flunitrazam binding to CBR was not affected. Additionally, they used [3H]DAA1106 to
characterize binding,

calculating affinity mitochondrial values of 0.12±0.03 nM.118

Autoradiography in rat brain demonstrated that [3H]DAA1106 corresponded to [3H]PK11195
localization, and DAA1106 behaves as a receptor antagonist.119
To create a PET tracer, [11C]DAA1106 (Figure 8)

OCH3
O

was synthesized by O-methylation with [11C]CH3I and
F
120

characterized.

N

In biodistribution data, the tracer
O

O

R

showed uptake in PBR-expressing tissues, including lung
and adrenals. Permeability of the blood-brain barrier was
found to exceed that of [11C]PK11195. The radiotracer
remained intact in brain.

However, in serum the

radiotracer was rapidly metabolized, and only 20% of the

[11C]DAA1106
[18F]FMDAA1106
[18F]FEDAA1106

R=11CH3
R=CH218F
R=C2H418F

Figure 8: Structures of PET analogs
of DAA1106

tracer was intact at 15 minutes post-injection.
The ligand [11C]DAA1106 has been examined in animal models as well as non-human
primate models and human patients with neuroinflammation. Four rat models of brain injury to
simulate neuroinflammation were used to look at DAA1106 distribution. [11C]DAA1106 uptake
was detected at the sites of injury.121-124 In two of these studies, uptake of [11C]DAA1106 was
compared to [11C]PK11195, and found to be better at localizing to the site of injury.122, 123 Brain
uptake in normal monkey was measured by PET, and specific uptake was seen in the occipital
16

cortex. Comparing [11C]DAA1106 and [11C]PK11195, DAA1106 was four times higher at 30
minutes post injection in the occipital cortex, and displaced when a blocking dose was
administered.

124

Finally, in a small study early stage Alzheimer’s Disease patients were

compared to age matched controls. [11C]DAA1106 uptake was increased in several regions,
suggesting that the ligand may provide a sensitive measure of neuroinflammation.
Fluorinated derivatives were developed to utilize the improved radionuclide properties
of fluorine-18.

[18F]FMDAA1106, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoromethyl-5-

methoxybenzyl)acetamide,

and

[18F]FEDAA1106,

N-(5-fluoro-2-phenoxyphenyl)-N-(2-

[18F]fluoroethyl-5-methoxybenzyl)acetamide, (Figure 8) were derived from DAA1106 to create
longer-lived tracers.125 [18F]FEDAA1106 displayed improved specificity for PBR and was not
metabolized in rat brain. [18F]FMDAA1106 bound similarly to DAA1106 but was metabolized in
the brain. The authors studied these tracers in further detail using biodistribution and PET in
normal monkey brain.126 [18F]FMDAA1106 defluorinated over the course of the study, while
[18F]FEDAA1106 did not. [18F]FEDAA1106 displayed improved stability in mouse serum, with
almost 40% intact at 15 minutes, while [18F]FMDAA1106 was rapidly metabolized. Metabolite
analysis with monkey plasma showed that [18F]FEDAA1106 was more stable than mouse serum
(56% vs. 30% at 30 minutes). In the biodistribution study, uptake was greater in PBR-expressing
organs, with highest uptake in the lungs as seen with [11C]DAA1106. The longer lived half-life,
coupled with the increased affinity for PBR and metabolic stability suggest that [18F]FEDAA1106
may be a useful, improved PET ligand for PBR.
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Summary
The Peripheral Benzodiazepine Receptor presents an interesting target for
characterization of tumors and inflammation. In recent years understanding of PBR has evolved
and encouraged the development of radiopharmaceuticals for non-invasive detection of this
biomarker. While PBR upregulation has been noted throughout the body, to date the focus of
imaging applications has concerned applications in the CNS.
This dissertation will examine the potential of imaging PBR sites in locations outside of
the CNS. The investigation will examine cell culture studies using proliferation and malignancy,
and evaluate potential correlations with PBR expression. In vivo localization of radioligands
specific to PBR will be evaluated in rodents and compared to established biomarkers for tumor
metabolism and DNA synthesis. The study examines PBR expression in tumors and concludes
with a comprehensive evaluation of the utility of PBR as a target site for oncological PET
imaging.
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Chapter 2

Cellular Expression of Peripheral Benzodiazepine Receptors:
Comparison to Proliferation and Malignancy
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Introduction
The Peripheral Benzodiazepine Receptor (PBR, or TSPO and ω3 alternatively) was
identified in 1977.1

It has been characterized as a complex containing three primary

components: the isoquinoline binding protein (IBP), voltage dependent anion channel (VDAC)
and the anion nucleotide carrier (ANC).2 PBR has been found to have higher expression in
steroidogenic tissues, with moderate to low expression in several other organs.3-5 Tumor cells
from several types of tissues have also been examined and noted to express PBR.6-9 The protein
is normally found at the mitochondrial membrane.4 However, it has been seen that the protein
also localizes to the nuclear membrane in malignant cancer cell lines.7, 10
Several roles have been attributed to PBR, including proliferation7, 11 and apoptosis,12-14
although tissue type may in part dictate the action of the protein. Studies on tumor lines
suggest an important role for PBR in tumor development, but the precise involvement has not
been determined. One trend seen in literature is a correlation between PBR expression and
proliferation.15 Studies with antibodies against markers like Ki-67 (MIB-1), a known tumor
proliferation marker,16 or glucose utilization by [18F]FDG demonstrate a relationship correlating
PBR and proliferation.18
PBR has also been correlated to malignancy. For instance, several investigations have
suggested that PBR could serve as a biomarker for glioma tumor grade differentiation.9, 17, 19, 20
In an in vitro study with glioma cell lines, Veenman et al. found a positive correlation for colony
size in a soft agar assay, a method to determine survival, and [3H]PK11195 specific binding.21
Several conflicting reports are found in breast cancer literature. In a study on patient
biopsy samples, PBR expression correlated with Ki-67.22 They found that lymph node negative
patients had a poorer prognosis when PBR levels were higher, and suggested that perhaps the
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protein could be a prognostic biomarker. In cultured cells, [3H]PK11195 uptake was measured
and compared to several cell characteristics.7 They analyzed cell proliferation in the presence of
several concentrations of PK11195, as well as performing in vitro assays of aggression. Their
data suggest a positive correlation between PBR expression and invasion potential. In this
paper, they also looked at metastatic patient samples compared to normal breast tissue
expression of PBR. Tumor samples had greater quantities of PBR, and perinuclear localization
was not found in normal tissue samples.
However, a later reference from the same group resulted in different data. Two clones
were created of MDA-MB-231, a breast cancer cell line characterized as a high PBR expressor.
One clone was a “low” expressor and the other was a “high” expressor.23 Scatchard analysis
using [3H]PK11195 show a Bmax that is approximately doubled in the “high” expressor compared
to the low expressor. In vitro proliferation was measured as was chemoinvasive potential, and
these characteristics were found to be similar in both cell lines. However, the “high” expressor
clone was able to form tumors in SCID mice whereas the “low” expressor clone could not.
Analysis revealed that they were of the same genetic linage, and chromosomal abnormalities
were shared. No conclusive explanation for the capacity to form tumors was given, but the
suggestion is made that a minimum PBR level may be required for PBR to act in cell
proliferation.
In order to better understand the cells we implant, cell characterization became
necessary. For each cell line, a variety of properties were assessed in vitro. These in vitro
measurements include proliferation studies, measures of aggression such as motility and
survival, and determination of PBR expression.
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Cell lines used in the studies described below include: MCF-7, MDA-MB-468 and MDA-MB-231.
These are all breast cancer cell lines that were purchased from ATCC (Manassas, VA). MDA-MB435, is a cell line that was classified as a human breast cancer line when these studies began, but
is now identified as a melanoma cell line.24 MDA-MB-435 was provided by Dr. Janet Price at MD
Anderson (Houston, Texas), and used with her permission. MCF-7 (ER-) clone was given by Dr.
Antonio Rosato at University of Padua, Italy, and used with his permission. MDA-BGL2 is a clone
of MDA-MB-231 which has been selected for its potential to form metastases; this cell line was
used with permission of Dr. Kathy Weilbaecher, at Washington University.
Quantifying PBR expression
Western Blot
Western blot analysis was the first method applied to analyze the expression of PBR in
cells. Cells were grown in T-75 flasks (BD Falcon), and maintained at 5% CO2. Media was
removed from the cells, and cells were washed twice with phosphate buffered saline (PBS).
Collection by scraping was followed by centrifugation at 2000g for five minutes. Supernatant
was removed and lysis buffer was added. Lysis buffer was made by diluting 10X Lysis Buffer (Cell
Signaling Technology) to 1X with MQ water and 7X protease inhibitor, from Complete Mini
Protease Inhibitor Cocktail Tablets (Roche) dissolved in MQ water. 100 µL of lysis buffer was
added to each microfuge tube of cells and placed on ice for 15 minutes before centrifugation at
16,000g for 10 minutes at 4°C. Supernatant was removed and analyzed by BCA Assay (Pierce
Biotechnology) for protein concentration.
BioRad Mini Protean Cell was used with a BioRad Ready Gel (12% Tris-HCl, 30 µL per
well).

The molecular weight standards used were the Dual Color Precision Plus Protein

Standards (BioRad). 10 μg total protein were added to each lane in 25 μL. 10X Tris/Glycine/SDS
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Buffer (BioRad)
ioRad) and 10X Tris/Glycine Buffer (BioRad) were diluted to make running buffer and
transfer buffer. Following transfer to PVDF, the blot was blocked with 5% milk in Tris Buffered
saline with 0.05% Tween-20
20 (TBST). Rabbit anti
anti-PBR
PBR (Santa Cruz) diluted 1:1000
1:
in TBST was
incubated overnight at 4°C, washed, and the blot was probed with Goat anti-rabbit
anti
IgG,

Figure 1: Western Blot on cultured cell lines with the Santa Cruz anti-PBR
PBR antibody. Bands are
seen at 75, 62, and 50 kDa. The monomer (18 kDa) is not present in significant quantities.
Dylight™647 (Pierce Biotechnology) at 2:15,000 in TBST at room temperature (RT) for one hour.
The blot was developed with ECL (Amersham). Overnight eexposure
xposure is shown below
bel in Figure 1.
The standard protein ladder (lanes 1 and 6), MCF
MCF-7
7 (lanes 2 and 7), MDA-MB-435
MDA
(lanes
3 and 8) and MDA-MB-468
468 (lanes 4 and 9) are shown in Figure 1. There is very little monomer
present at 18kDa (IBP). Bands are seen at 50, 62 and 75 kDa. These may be attributed
a
to the
trimer (~80 kDa), or all may be IBP multimers. However, there was not a control protein so this
experiment was repeated with additional cell lines and recombinant PBR Control Protein
(Trevigen). Unfortunately, after initial success with the Santa Cruz anti-PBR
PBR antibody, I was
unable to reproduce the data despite many attempts to do so. The standard protein was
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detected at approximately 20 kDa, which is the predicted weight for the GST-tagged
GST
recombinant protein, but no bands were visible in sample lanes.

Figure 2: Western blot on cultured cell homogenates with the Trevigen anti-PBR
anti
antibody.
Streaking was seen in lanes sporadically and increased with film exposure.
Another rabbit anti
anti-PBR
PBR antibody was purchased (Trevigen) and used to probe for PBR.
With this antibody, multiple bands are detected in the samples (lanes 44-8
8 below), but there was
variable streaking in samples that would become more intense with extended exposures (Figure
2). Efforts were made to resolve the issue, but it could not be prevented. Therefore, we
concluded that another method would be required to measure PBR expression.

ELISA
The enzyme linked immunosorbent assay (ELISA) is an alternative method to quantify
proteins. It is a plate-based
based assay. There are two options when using ELISA, the direct or in the
indirect ELISA.
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In indirect ELISA the antigen, the protein of interest, is coated on the wells of the 96well plate. After one hour wells are rinsed and blocked with a 2% bovine serum albumin (BSA)
solution. Primary antibody is incubated at 37°C for 1.5 hours followed by secondary antibody
conjugated to horse radish peroxidase (HRP) for one hour incubation at 37°C. Washing well to
ensure that all unbound antibodies are removed, HRP substrate is incubated at RT for 20
minutes. Reaction is stopped with the addition of acid. Plates are read at 490 nm.
The method described above was utilized with both the Santa Cruz Biotechnology antiPBR and Trevigen anti-PBR as the primary antibody. The secondary antibody was a donkey antirabbit IgG, conjugated to HRP (Amersham Biosciences). Substrate was SigmaFast® o-phenylene
diamine dihydroxychloride tablet (Sigma) dissolved in water.
The antigen was the Trevigen recombinant protein with a GST tag, suspended at a
concentration of 9.80x10-6 M (0.2 mg/mL). Antigen was diluted to measure the absorbance with
a standards curve. Dilutions ranged from 78 picomoles in 100 μL to 40 femtomoles in 100 μL.
For wells in which the 40 fmoles was added (2 μg protein), this would be equivalent to 20
pmoles PBR in a total of 1 mg protein.
Figure 3 shows a standard curve. Little difference is seen in absorbance below 20
fmoles PBR/ 2 μg total protein (10 pmoles/mg protein). Literature quantifies the expression of
MDA-MB-231 cells, PBR positive controls to be approximately 10 pmoles/mg protein.23 Since
the cell lines that are accepted as high expressing positive control cells are at threshold for
detection of differences in absorbance, this method will not be useful for measuring a range of
PBR expression.
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Figure 3: Sample data from a standards curve for the indirect ELISA using Trevigen
recombinant PBR to determine assay sensitivity.

In direct or “sandwich” ELISA, a primary antibody is coated on the wells of the 96-well
plate (TPP) and allowed to incubate overnight at 4°C to allow complete binding. The next day,
wells are rinsed and blocked with a 2% BSA solution. Antigen, the recombinant PBR, is added
followed by 2.5 hour incubation with an anti-PBR primary antibody from a different species. By
doing this, cross reactions between any unbound antibody on the surface of the well will be
avoided. Secondary antibody conjugated to HRP incubated for two hours at 37°C. Washing well
to ensure that all unbound antibodies are removed, HRP substrate is incubated at RT for 30
minutes. Reaction is stopped with the addition of acid. Plates are read at 490 nm.
The technique was executed as described above. The coating antibody was a chicken
anti-PBR antibody (GenWay Biotech). Both the Santa Cruz and Trevigen anti-PBR were used for
detection with the same Amersham secondary as above. Trevigen recombinant control PBR
protein was diluted at the same concentrations for the direct ELISA.
Useful data could not be generated with the sandwich ELISA method. With this method
equal absorbance was seen at all concentrations. When conditions were tested to determine
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the reason why the absorbance did not vary, data shown in Figure 4 provided an explanation.
The conditions are described with abbreviations, and the order indicates the above sequence of
primary/PBR standard/primary/secondary. In the red bars, the GenWay antibody was coated
followed by PBR protein (P) or not (N), Trevigen antibody and secondary. Orange equals
GenWay, PBR protein, Trevigen antibody and no (N) secondary. Green bars are GenWay
antibody, PBR protein (P) or not (N), Santa Cruz anti-PBR, and secondary. In blue, it is GenWay,
PBR protein, Santa Cruz anti-PBR and no (N) secondary. What is shown is that there is very little
difference whether the PBR control protein is added to bind the Trevigen or Santa Cruz anti-PBR
antibody. When BSA is coated onto the plate in the place of GenWay and when Trevigen or
Santa Cruz is substituted by a BSA solution, absorbance is equal to the blank. We conclude that
the two primary antibodies are interacting, and thus the absorbance is equal regardless of the
PBR added.

0.25

Abs at 492 nm

0.2
0.15
0.1
0.05
0

Figure 4: Direct or sandwich ELISA data demonstrating that the antibodies are interacting. In
the red, using the Trevigen anti-PBR, absorbance is similar when PBR recombinant protein is
not added to bind the coating antibody. In orange, the absence of secondary antibody
reduces the absorbance to blank absorbance. In green, the same observation of unchanged
absorbance is seen when no PBR standard protein has been added, while the absence of
secondary reduces absorbance.
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Comparison of [11C]PK11195 Uptake
At this point, studies had begun measuring the in vitro cellular uptake of the
radiopharmaceutical [11C]PK11195. This assay is more applicable for comparison to in vivo
studies, since it requires the uptake of the radiopharmaceutical. Therefore, with the difficulties
encountered in attempts with the above techniques to quantify PBR expression, we pursued this
assay to measure PBR levels.
Radiopharmaceutical synthesis: (R)-N-desmethyl PK11195 (ABX GmbH, Germany) is
methylated by [11C]CH3I produced on the GE PETtrace MeI MicroLab in a method based on
Camsonne et al.25 Substrate was dissolved in DMSO (250 μL) with 15% KOH (3 μL) added prior
to [11C]CH3I delivery. After [11C]CH3I has been trapped, the reaction mixture is heated at 90°C (3
minutes). Preparative reverse phase HPLC separation is performed with a mobile phase of
actonitrile/ammonium formate buffer. The radioligand was reformulated in 10% ethanol in
normal saline. Overall synthesis time is 60 minutes from the end of bombardment, and batch
yields were 0.26 to 0.54 GBq (10-20 mCi), with radiochemical purity greater than 99% and
specific activity exceeding 37 TBq/mmol (1,350 Ci/mmol).
Cell uptake studies: Cells were grown in 6-well plates (Co-star) to be at 70-80%
confluency. Media was changed before the addition of the radiopharmaceutical. For blocking,
200 ng of cold N-methyl-PK11195 (ABX GmbH, Germany) was added thirty minutes prior to the
addition of the radiopharmaceutical. A solution of [11C]PK11195 was added to each well. Cells
were incubated for 0, 10, 30, and 60 minutes. After removing the media, cells were washed and
lysed. Media, washes and cell lysates were counted by gamma counter to determine the
percent uptake for the cells. BCA Protein Assay (Pierce Biotechnology) was performed to
normalize for protein levels. Data was normalized to %ID/g representing the fraction of the
total radioactivity added to the media that was bound per gram of protein.
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Figure 5 shows averaged data from several studies (n=3). The amount of uptake in the
presence of 200 ng cold PK11195 was subtracted from normal uptake conditions to calculate the
net %ID/g protein. Distinct
uptake of [ C]PK11195 is
seen for the MDA-MB-435
while the uptake by MDA-

%ID/g protein

11

MB-468 could be catagorized
as moderate. MCF-7 displays
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in Figure 5: Net Uptake for [11C]PK11195 in cultured cells showing
differential uptake of the PBR ligand in vitro. The trends seen
agreement with data from correspond to literature
literature.7
Measuring Proliferation Potential
PBR has been suggested to play a significant role in proliferation due to observed
correlations of PBR expression and proliferation. Support for this hypothesis is that when the
cell line MCF-7, which has very little natural expression of PBR, was stably transfected with PBR,
there was a five-fold increase the binding of [3H]PK11195, and proliferation was increased.
When siRNA targeting PBR was introduced in MDA-MB-231 cells, a significant reduction in
[3H]PK11195 binding and proliferation measured by BrdU were observed.11
we wanted to evaluate our cell lines and establish proliferation parameters.
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In these studies,

Cell Counts Method
This is a very straightforward method to determine the proliferation potential for each
cell line. Cells were harvested from a T-75 flask using Trypsin/EDTA (Washington University
Tissue Culture Support Center), and counted using a hemocytometer. Cells were resuspended in
fresh media for addition to a 24-well plate (Costar). Cells were plated at three densities: 1x105
cells/mL, 5x104 cells/mL, and 1x104 cells/mL in total volume of 1 mL. Each day three wells were
washed with PBS and trypsinized from each density. Using 1:1 trypan blue, each sample was
counted twice. The six values were averaged for the growth curve. Data are plotted as shown
in Figure 6. A line is drawn where the proliferation is linear, and proliferation rate was
calculated by determining the population doubling time (PDT) as shown as follows:
r = 3.32 [log (Nf) – log (Ni)] / (Tf - Ti)
PDT = 1/r
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Figure 6: Proliferation curves generated by cell counting with a hemocytometer for selected
cell lines showing fast (MDA
(MDA-BGL2) and slow proliferation (MDA-MB-468).
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MTS Assay
A second method was used to confirm the data on proliferation. Cell counts in logphase growth are very low, leading to less certainty in the values obtained. In the ideal, in each
1 mm2 area on the hemocytometer, there would be between 20 to 50 cells. For my studies, the
number of cells in the 1 mm2 area was typically below the ideal threshold for the first three to
four days after the subculturing to the 24 well plates.
The MTS Assay kit that was used was the Promega Cell Titer® Aqueous non-radioactive
cell proliferation assay kit.

There are two solutions, a tetrazolium compound 3-(4,5-

dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS) and an electron coupling reagent, phenazine methosulfate or PMS. After opening, the
two reagents can be combined and stored at -20°C for a year, thawing in the water bath when in
use. MTS is reduced by cells to form a formazan product. The absorbance of the formazan
product at 490nm can be measured in 96-well assay plates. The extent of MTS reduction is
proportional to the number of cells present within a range of linearity (Figure 7).

3

y = 2E-05x + 0.352
R² = 0.971
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Figure 7: Standards curve for MTS with MDA-MB-435 cells. The line drawn
indicates the linear data that can be used to quantify the number of cells
present in each well of the 96-well plate. The equation is displayed.
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When using the MTS assay, on the day that cells are subcultured into the 96-well plates,
a standards curve must be made. As shown in Figure 7, a typical curve would have points below
the linear region and a plateau at the upper limits of the cell densities. The cells are subcultured
at the lower limits of detection so they will grow into the linear zone. When cells are dividing in
log phase growth, apply the equation shown above to calculate population doubling time.
6.E+04
5.E+04
4.E+04
cell counts

3.E+04
2.E+04
1.E+04
0.E+00
0.0

50.0

100.0

150.0

Time (hours from subculture)

Figure 8: Sample MTS Data Curve for MDA-MB-435 over the linear range of
growth as determined by the standard curve.

Figure 8 shows a sample data set for the MDA-MB-435 cell line. The shortcoming of the
MTS method is in the narrow window for calculating data. As shown in Figure 8, the time for
viable cell count approximation is less than an order of magnitude, and the line does not form a
true exponential shape in growth.
Results and Summary of Measuring Proliferation Potential
Data is reported in Table 1. Both methods have short-comings, but the MTS assay is
slightly better for the determination of PDT. This is because its range of utility, though narrow,
more closely corresponds to the early time points when cells would be most rapidly dividing. In
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contrast, the small number of cells in the hemocytometer 1 mm square is at or below the
threshold for confidence.
Table 1: Maximum population doubling time (in hours) as determined by the two methods.
MCF-7
(ER-)

MDA-MB435

MDA-MB468

14

16

33

17

18

47

MTS
Assay
Cell
Counts

MDA-BGL2

MDA-MB231

MCF-7

13.7

30

39

9

41

42.5

(MDA-MB231)

(ER+)

Defining Cell Aggression
How do you define aggressive when describing a tumor? Historically, the PET view has
been centered on [18F]FDG which, as a glucose analog, will localize to a tumor due to elevated
metabolism.

Radiopharmaceutical development has moved from this simplistic view to

embrace a more descriptive characterization, such as antibodies targeting proteins important in
establishing tumor vasculature. From a molecular biology perspective, there are an infinite
number of ways to characterize aggression.
My focus was on motility and survival. Motility, distinct from chemoinvasive potential,
addresses the simple migration of the cells to an unoccupied space. Chemoinvasion is the
capacity of the cell to penetrate a cellular barrier such as the extracellular matrix. Another way
to describe survival would be heartiness. Some cell lines may not form tumors quickly, but are
able to survive unfavorable conditions. With assistance from personnel in Dr. Harbour’s lab, I
performed “wound-healing” assays to measure motility and soft agar assays to measure
survival.
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Migration Assay
The “wound-healing” assay was performed using 60 mm dishes that had been
previously marked with 2 mm circles to provide reference points. Cells were grown in the dishes
to approximately 80-90% confluency. “Wounds” were made using a cell scraper. Media and any
floating cells were removed. Pictures were quickly taken using a microscope and fresh media
was added. The dishes were kept in the appropriate incubator (5% CO2 or no CO2) at 37°C
between handling. At 24 hour intervals, out to 72 hours post-wounding, images were taken on a
Nikon Eclipse E600 microscope with digital camera DXM1200F. Analysis was performed using
ImageJ (NIH) to quantify the amount of wound tract that had been filled in by new cells,
quantifying the open “wound tract” in pixels each day and calculating the % “wound tract” filled
at each time point by comparison to image taken immediately after creating the “wound”.
Migration Results and Summary
Figures 9 and 10 show the data from the wound-healing experiments. In Figure 9, the
data is graphed for comparison. In Figure 10, a visual comparison is provided for the cell lines.
As shown in Figure 9, the cell lines migrate into the “wound tract” at different rates. The PBR
positive control cells, MDA-MB-231 (Figure 10A) and clone MDA-BGL2, have similar rapid
response and quickly move into the void space.

MDA-MB-435 (Figure 10B) moves at a

consistent rate into the tract and has mostly “healed” in 72 hours. MDA-MB-468 (Figure 10C)
and MCF-7 (Figure 10D) cells do not display significant “healing” response in 72 hours.
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100%
90%

%" wound tract" filled

80%
70%

24 hour

60%
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50%
40%

72 hour

30%
20%
10%
0%

Figure 9: Data for in vitro wound-healing demonstrating the different
responses for each cell line when a “wound” was created.
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A. MDA-MB-231
0 Hours

24 Hours

48 Hours

72 Hours

B. MDA-MB-435
0 Hours

48 Hours

24 Hours

72 Hours
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C. MDA-MB-468
0 Hours

24 Hours

48 Hours

72 Hours

D. MCF-7
0 Hours

48 Hours

24 Hours

72 Hours

48

Figure 10: Selected wounds from cell lines representing high to low rate of "healing" in the
wound tract over a 72 hour period. A. MDA-MB-231, B. MDA-MB-435, C. MDA-MB-468, and
D. MCF-7.
Cell Survival
The soft agar assay measures the capacity of the cells to survive and grow in the
absence of a growth surface. The capacity for anchorage-independent growth is a marker that a
cell has undergone malignant transformation. For this assay, cells were cultured to be in log
phase growth. On the first day of setting up the experiment, a twelve-well plate (TPP) was
prepared by adding 1 mL of 0.8% agar (Invitrogen Ultra Pure L.M.P. Agarose) in sterile PBS
(Cellgro) and media. A stock solution of 3% agar was made in PBS, and diluted to 0.8% with
media. The plate was moved to 4°C for 10 minutes to allow the agar to set, and returned to RT.
On the following day, cells were harvested and counted. Cells were suspended in a 0.3% agar
solution (3% PBS stock solution diluted with media) to concentrations of 5x105, 1x105, and
5x104. This cell dispersion was added to the 12-well plate on top of the 0.8% agar. The plate
was moved to 4°C to allow the agar to set and returned to RT. The 12-well plates were
incubated for 14 days. To visualize colonies, crystal violet solution (Sigma) was added. Colonies
were counted under a microscope, with the standard of 350 μm as the minimum diameter for a
colony to be counted.
Results and Summary of Anchorage-Independent Growth
Figure 11 shows data comparing the cell lines in the soft agar assay. The cell line MDAMB-435 had an average of 416±51, followed by MDA-BGL2 with 312±54 colonies in each well.
MDA-MB-468 and MCF-7 (ER-) had fewer colonies at 99±29 and 80±36, respectfully. Therefore
the MDA-MB-231 clone MBA-BGL2 and MDA-MB-435 have greater malignancy as measured by
anchorage-dependent growth.
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MDA-MB-435
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Figure 11: Anchorage-independent growth data using the soft agar assay. Two groups are
seen the low colony counts for MCF-7 (ER-) and MDA-MB-468, while the MDA-BGL2 and MDAMB-435 were able to form a greater number of colonies over the two week incubation.

Data Summary
Data for the assays performed in this chapter is in summarized in Table 2. As shown in
Table 2, different levels of uptake were seen for [11C]PK11195 uptake in vitro for the cell
cultures. Two PBR positive control cell lines, MDA-MB-231 and the clone MDA-BGL2, were also
used. When PBR levels are compared against proliferation, there is a no correlation. Though
the cell line MDA-MB-231 does not display rapid proliferation, the MDA-MB-231 clone MDABGL2 does. MDA-MB-435 had the highest uptake of [11C]PK11195 at 58.5% ID/g protein and a
PDT of 16 hours by MTS. MDA-MB-468 had a longer PDT of 33 hours and moderate uptake of
[11C]PK11195 (26.8% ID/g). Meanwhile, MCF-7 (ER+) had a population doubling time that was
only slightly longer than MDA-MB-468 (39 hours) with a much lower uptake of [11C]PK11195 at
1.62 % ID/g protein, in keeping with reported data for MCF-7. Within these cell lines, there is no
association of PBR and population doubling time.
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Table 2: Summary of Data

MCF-7
(ER-)

MDA-MB435

MDA-MB468

MDA-BGL2
(MDA-MB231)

MDA-MB231

MCF-7
(ER+)

%ID/g
11
[ C]PK11195

--

58.5

26.8

--

--

1.62

MTS
Assay

14

16

33

13.7

30

39

Cell
Counts

17

18

47

9

41

42.5

“Wound- Healing”
( at 72 hrs)

26%

80%

40%

100%

100%

--

Soft Agar Assay
(colonies)

80 ± 36

416 ± 51

100 ± 29

312 ± 53

--

--

When PBR levels are compared to the data for aggression, there is a positive correlation.
Both of the PBR positive control cell lines had completely “healed” at 72 hours, and in fact both
had done so in less than 48 hours. This effect could be due to rapid proliferation in the MDABGL2 cells. However, the observation of nearly identical “healing” in the MDA-MB-231 line with
a reduced proliferation rate and the lack of similar behavior in MCF-7 cells with high
proliferation eliminates that concern. MDA-MB-435 had the highest [11C]PK11195 uptake, and
has the highest values for amount of “wound tract” that “healed” and average quantity of
colonies that formed in the anchorage-independent growth assay.

MDA-MB-468 had a

moderate uptake of [11C]PK11195, and displayed reduced capacity to “heal” and form colonies
compared to both MDA-MB-435 and MDA-BGL2. MCF-7 is a low PBR expressing cell line and
displays reduced “healing” and colony formation.
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Chapter Summary
In this chapter, human breast cancer cell lines were characterized for their PBR
expression, proliferation and aggression. Using [11C]PK11195 in whole cell uptake assays, there
were significant differences in the specific uptake of the radiopharmaceutical. Population
doubling time was calculated by the cell counting method and the MTS assay. To characterize
aggression in vitro the “wound-healing” assay measured the migration of cells, and the soft agar
assay probed the capacity of the cells to grow in an anchorage-independent environment.
Comparing the data for expression to the data for proliferation, there was no
discernable trend. Cell lines with similar population doubling times had different levels of PBR
expression.

Two clones of a positive control, the MDA-MB-231 cell line have significant

variation in PDT, indicating that PBR is not important in proliferation.
However, there is a positive correlation for PBR expression and aggression. In the
positive control cell lines, there was rapid “wound-healing” and formation of colonies. In MDAMB-435 cells, which displayed elevated expression of PBR, there was migration and pronounced
capacity to grow in the soft agar assay. For the MDA-MB-468, moderate PBR expressing cell
line, there is partial “healing” in the “wound tract” and a reduced number of colonies. For the
ER negative clone of the non-aggressive tumor cell line MCF-7, there is limited migration into
the “wound tract” and colony formation.
The data is in agreement with literature. In fact, molecular biologists have conducted
more thorough exams of cell lines, measuring cell characteristics with a litany of tests. To
condense the findings, PBR is found at elevated levels in neoplastic tissues and there is a
correlation between the expression of PBR and malignancy in vitro and ex vivo. Higher PBR
levels would suggest a poor prognosis, so PBR may be a useful biomarker in characterizing
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tumors although this has only been explored in vivo for gliomas and astrocytomas. Tumors
located outside of the CNS have not been investigated in vivo. The next chapter will describe
our experiments designed to investigate PBR radioligand distribution and compare it to the
localization of two PET radiopharmaceuticals widely used in vivo tumor imaging.
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Chapter 3

Animal Studies Targeting PBR
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Introduction
PET imaging provides a non-invasive tool for the characterization of tumors. PET tracer
[18F]FDG, 2-[18F]fluoro-2-deoxyglucose, measures the metabolism of the cell by glucose
utilization, while [18F]FLT, 3’-deoxy-3’-[18F]fluorothymidine, is an analog for thymidine and
substrate for Thymidine Kinase 1, a biomarker for proliferation.1 In recent years, several
additional proteins have been identified as potential biomarkers for tumor characterization.
One of these is the Peripheral Benzodiazepine Receptor2, which has been characterized
as both a marker for proliferation and malignancy.3-6

The ligand [11C]PK11195, 4’-

chlorodiazepam,7-chloro-1,3-dihydro-1-methyl-5-(p-chlorophenyl)-2H-1,4-benzodiazepin-2-one,
(Figure 1A) has been utilized for PET imaging of neuroinflammation and gliomas.4, 7-10 Other
ligands have been developed as derivatives of PBR specific Ro5-4864 and PK11195. Several
promising compounds have been synthesized, including DAA1106 analog [18F]FEDAA1106
(Figure 1B).

However, while PBR was found to be upregulated in brain and peripheral tumors,

imaging has not addressed tumors located outside of the central nervous system.
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Figure 1: Chemical
structures of [11C]PK11195
(A) and [18F]FEDAA1106 (B),
specific ligands for PBR. Site
of radiolabel is indicated.

The overexpression of PBR is not found in all types of cancer11, but is nonetheless found
in cancer of many tissue types. These include colon12, breast3,
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6, 13

, prostate14, and liver15

carcinomas.

The application of imaging would add valuable information by allowing the

characterization of the whole, heterogeneous tumor rather that the small biopsy sample. In
colon cancer, advanced stages had elevated PBR levels compared to lower grade tumors.
Additionally, patients with low PBR expressing tumors had a much greater (80% versus 20%)
chance of survival when followed approximately ten years after diagnosis.16

Several

investigations have demonstrated that breast tumor biopsies have higher expression of PBR
over normal breast tissue.3, 6, 11 Such examples demonstrate the potential value of PET imaging
of PBR for better characterizing individual tumors.
Therefore, we conducted experiments designed to consider the protein PBR as a
biomarker. In breast tumor-bearing animals, radiotracer uptake was measured by small animal
imaging and ex vivo biodistribution studies. Tumor-implanted rodents were imaged in a threeday sequence for direct comparisons of radiotracer distribution and tumor localization. We ask
the question: can PBR ligands differentially localize to tumor sites?
I.

Preliminary Comparison of Radiopharmaceuticals In Vivo
Our first study exploring the potential for PBR as a PET biomarker was a straightforward

examination of tumor-bearing mice.
A) Tumor-bearing mice. Nu/Nu female mice had breast cancer cells implanted in the
mammary fat pad. Cell lines that were used included: MDA-MB-468 (a breast cancer cell line
identified to express PBR3), MDA-MB-435 (a cell line that is now classified as a melanoma but
was thought to be of breast tissue origin prior to genetic analysis)17, and MDA-MB-231 (a breast
cancer cell line that is considered to be a positive control for PBR).

59

B)

Radiopharmaceuticals: [18F]FDG, a glucose analog; [18F]FLT, a fluorinated

derivative of thymidine; [11C]PK11195, an isoquinoline that was identified for its high affinity for
the peripheral benzodiazepine receptor and widely accepted standard ligand for PBR.
a. Radiosynthesis of [18F]FDG: [18F]FDG was synthesized on the Coincidence FDG Synthesis
Module in high specific activity.
b. Radiosynthesis of [18F]FLT: 5'-O-(4,4'-dimethoxytrityl)-2,3'-anhydrothymidine (ABX,
GmbH, Germany) is fluorinated by [18F]fluoride produced by the

18

O(p,n)18F reaction through

proton irradiation of enriched 18O water. Overall synthesis time is 110 minutes from the end of
bombardment, and had radiochemical purity greater than 99% and specific activity exceeding 74
TBq/mmol (2,000 Ci/mmol).
c. Radiosynthesis of [11C]PK11195: (R)-N-desmethyl PK11195 (ABX GmbH, Germany) is
methylated by [11C]CH3I produced on the GE PETtrace MeI MicroLab in a method based on
Camsonne et al. Substrate was dissolved in DMSO (250 µL) with 15% KOH (3 µL) added prior to
[11C]CH3I delivery. After [11C]CH3I has been trapped, the reaction mixture is heated at 90°C (3
minutes). Reverse phase HPLC preparative separation is used with ACN/ ammonium formate
buffer mobile phase. Product was reformulated in 10% ethanol in normal saline. Overall
synthesis time is 60 minutes from the end of bombardment, and batch yields were 0.26 to 0.54
GBq (10-20 mCi) with radiochemical purity greater than 99% and specific activity exceeding 37
TBq/mmol (1,350 Ci/mmol).
C) Imaging and biodistribution studies.

All animal experiments were conducted in

compliance with the Guidelines for Care and Use of Research Animals established by
Washington University’s Animal Studies Committee. Tumor-bearing mice were monitored to
observe tumor development. CT co-registration was performed (ImTek microCAT II, Knoxville,
TN, USA) to obtain a full anatomical image. PET imaging studies were performed on a microPET
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Focus scanner or on a microPET F120 (Concorde Microsystems, Knoxville, TN, USA).
Radiopharmaceutical was given by tail vein injection and animals were imaged at one hour postinjection. For imaging, mice were anesthetized under oxygen with isofluorane.
In biodistribution studies, blood, tumor and organs of interest are collected after an
animal has been killed by cervical dislocation while anesthetized. Each is individually counted in
a γ counter and later weighed. Uptake is reported as % injected dose (% ID/organ) and %
injected dose per gram tissue (% ID/g) for each sample by comparison to known samples.
Results:
Figure 2 shows two breast cancer tumor models which were analyzed with [18F]FDG.
Post-PET biodistribution data supports observations seen in the images, with greatest uptake in
the heart. MDA-MB-435 tumors had approximately 3% ID/g localize to the tumor tissue, while
MDA-MB-231 had slightly more radiopharmaceutical localization (3.7% ID/g).
In Figure 3, [18F]FLT localization for a selected MDA-MB-231 tumor-bearing mouse is
shown. As the images indicate, when compared to FDG, FLT is more equally distributed
throughout the upper torso, and liver uptake has more than doubled. Tumor localization (3%
ID/g) as determined by post-PET biodistribution experiments is similar to [18F]FDG.
In Figure 4 [11C]PK11195 localization is shown. Despite elevated uptake in the chest,
tumors located in the mammary fat pad (under the front limbs) are still distinguished.
Biodistribution ex vivo confirms radiopharmaceutical localization imaged in vivo.
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A

B

Figure 2: AMIRA Co-registered
registered images from mice implanted in the mammary fat pad
p imaged
with [18F]FDG. In A, MDA-MB
MB-231 and in B, MDA-MB-435 tumor-bearing
bearing mice show good
radiotracer localization to the tumor, as well as high uptake in the heart
heart.
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Figure 3: Co-registered
registered images of a MDA
MDA-MB-231 tumor-bearing mouse with
18
[ F]FLT. Both right and left tumors, in the mammary fat pad, can be
visualized. Liver uptake of FLT is greater than FDG.

Figure 4: MDA-MB-435
435 tumor
tumor-bearing mice,, implanted at the mammary fat pad, imaged with
11
[ C]PK11195 at 60 minutes post
post-injection. Both tumors display significant radioligand uptake,
as do the lungs and heart.

Summary of Part I
Using small animal imaging followed immediately by ex vivo biodistribution, we compared
the localization of biomarkers FDG and FLT to the PBR lligand
igand PK11195, with favorable results.
This provides preliminary evidence for the utility of PBR as an imaging target with PET.

63

However, these preliminary studies were unable to compare uptake of tracers within a single
tumor. Therefore, a study using tumors as their own internal controls was done.
II.

In vivo comparison of radiopharmaceutical uptake

Study Methods:
A) Tumor cell lines selected for implant. Based on the in vitro uptake data for [11C]PK11195
shown in the last chapter, cell lines differential in expressed levels of PBR in the rank order of
MCF-7 < MDA-MB-468 < MDA-MB-435. MDA-MB-231 clone MDA-BGL2 was used to provide a
PBR positive control, as MDA-MB-231 is recognized as a high expressing cell line. When these
cells were implanted in nude mice, all developed into tumors. However, the rate of tumor
development for imaging varied among the cell lines.
B) Radiopharmaceuticals used. As in the previous studies, three tracers were compared:
[18F]FDG, [18F]FLT, and [11C]PK11195.
a. Radiosynthesis of [18F]FDG: [18F]FDG was synthesized on the Coincidence FDG Synthesis
Module in high specific activity.
b. Radiosynthesis of [18F]FLT: 5'-O-(4,4'-dimethoxytrityl)-2,3'-anhydrothymidine (ABX,
GmbH, Germany) is fluorinated by [18F]fluoride produced by the

18

O(p,n)18F reaction through

proton irradiation of enriched 18O water. Overall synthesis time is 110 minutes from the end of
bombardment, and had radiochemical purity greater than 99% and specific activity exceeding 74
TBq/mmol (2,000 Ci/mmol).
c. Radiosynthesis of [11C]PK11195: (R)-N-desmethyl PK11195 (ABX GmbH, Germany) is
methylated by [11C]CH3I produced on the GE PETtrace MeI MicroLab in a method based on
Camsonne et al. Substrate was dissolved in DMSO (250 µL) with 15% KOH (3 µL) added prior to
[11C]CH3I delivery. After [11C]CH3I has been trapped, the reaction mixture is heated at 90°C (3
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minutes). Reverse phase HPLC preparative separation is used with ACN/ ammonium formate
buffer mobile phase. Product was reformulated in 10% ethanol in normal saline. Overall
synthesis time is 60 minutes from the end of bombardment, and batch yields were 0.37 to 0.74
GBq (10-20 mCi) with radiochemical purity greater than 99% and specific activity exceeding 50
TBq/mmol (1,350 Ci/mmol).
C) Imaging and biodistribution studies.

All animal experiments were conducted in

compliance with the Guidelines for Care and Use of Research Animals established by
Washington University’s Animal Studies Committee. Ten Nu/Nu mice were implanted for each
cell line with bilateral mammary fat pad injections. The mice were monitored to observe tumor
development. Tumors were allowed to form until they reached a size ranging from 100 to 350
microliters. On the day of the study with FDG, CT was performed (ImTek microCAT II, Knoxville,
TN, USA) to obtain a full anatomical image. PET imaging studies were performed on a microPET
Focus scanner or on a microPET F120 (Concorde Microsystems, Knoxville, TN, USA).
Radiopharmaceutical was given by tail vein injection or via catheter. For imaging mice were
anesthetized under oxygen with isofluorane.
The animals were then imaged in a three day sequence with [18F]FDG, [18F]FLT and
[11C]PK11195.

Day 1 was either [18F]FDG or [18F]FLT, and Day 2 was the other

radiopharmaceutical. For both tracers, imaging was at one hour post injection. On the third
day, [11C]PK11195 was administered and imaged at twenty minutes post injection. If tumors
grew at a rate allowing two imaging courses, half of the mice (those with the larger tumors)
were killed for an immediate post-PET biodistribution study. For the second imaging course, all
imaged mice were used in a post-PET biodistribution study.
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In biodistribution studies, blood, tumor and organs of interest are sampled after an
animal has been killed via cervical dislocation. Each is individually counted in a γ counter and
later weighed. Uptake is reported as % injected dose (% ID) and % injected dose per gram tissue
(% ID/g) for each sample by comparison to standard samples.
PET data were analyzed with ASIPro® PET data analysis software (Concorde) to draw
regions of interest and measure radiopharmaceutical localization. Data is reported as standard
uptake value (SUV). Where post-PET biodistribution studies were performed with [11C]PK11195,
data was compared to ASIPro results for correlation between ex vivo and in vivo measurements.
Results:
Table 1 summarizes the data obtained, and Figure 5 shows representative images.
Several points can be made about the trends seen.

First, the relative uptake of

radiopharmaceuticals is approximately the same for [18F]FDG and [18F]FLT, while [11C]PK11195
displays significantly lower tumor uptake (uptake is at or below 1% ID/cc in ASIPro analysis).
Biodistribution data confirms that noninvasive in vivo measurements by ASIPro are as expected
based on ex vivo data. FDG and FLT uptake in vivo as determined noninvasively by imaging is
less than uptake measurements ex vivo due to the intrinsic limitations of the PET technique.
However, the image data correlates well with the dissection data, and demonstrates
significantly higher uptake for the metabolic/proliferation markers compared to PK11195.
[11C]PK11195 uptake does not indicate that tumor cells that express PBR would be detectable in
vivo using [11C]PK11195.
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Biodistribution
% ID

2.78
±
0.96
3.81
±
0.51
0.52
±
0.22
1.39
±
0.55
1.05
±
0.25

3.51
±
1.37
2.99
±
0.77
0.50
±
0.19
2.01
±
0.84
1.10
±
0.72

2.89
±
1.07
2.76
±
0.58
0.41
±
0.18

3.15
±
0.80
4.38
±
0.80
0.43
±
0.30

1.84
±
0.70
3.78
±
0.98
1.19
±
0.23

ND

ND

ND

ND

ND

ND

3.63
±
0.42
2.50
±
0.11
0.92
±
0.18
1.42
±
0.28
1.87
±
0.27

MDA-231

3.62
±
0.97
3.88
±
0.77
0.56
±
0.23
0.83
±
0.20
0.76
±
0.62

MDABGL2

MDA-468
(2nd)

Biodistribution
% ID/g

MDA-468

PK
%ID/cc

MDA-435
(2nd)

FLT
%ID/cc

MDA-435

FDG
%ID/cc

MCF-7
(2nd)

Tumor
Uptake

MCF-7

Table 1: Data summarizing the tumor localization of [18F]FDG, [18F]FLT, and [11C]PK11195
in tumor-bearing mice.

1.20
±
0.65
3.82
±
1.26
0.71
±
0.22
ND

ND

When the [18F]FDG and [18F]FLT data are considered, it is noted that when tumors that
are imaged in a second tracer study, there is a uniform reduction of radiopharmaceutical
uptake. This effect may be due to therapeutic of radiation exposure in the first study with CT
and small animal PET, or due to reduction of metabolism and cellular processes in larger,
established tumors compared to newly-formed tumors that are still in the process of
establishing a microenvironment.
The pattern of uptake of [18F]FDG and [18F]FLT is also noteworthy considering that the
MDA-MB-468 and MDA-MB-231 took a longer time to develop compared to the MCF-7 cells,
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Figure 5:: ASIPro images of the same MDA-MB-435
435 tumor bearing mice with [18F]FDG, [18F]FLT
and [11C]PK11195 imaged on three consecutive days. FLT and FDG localize to the site of the
tumor significantly more than PK11195. Biodistribution data confirms that the tumor uptake
of PK11195 is reduced
ced when compared to FDG and FLT.
which rapidly established themselves after implant. Cells that are able to establish tumors
quickly had more glucose metabolism, and [18F]FDG uptake, the MDA-MB-468,
468, which was slow
to establish primary tumor, showed more TK1 activity and [11C]PK11195 uptake.
Summary of Part II
The poor uptake of [11C]PK11195
11195 was disappointing and unexpected based on data
collected in the preliminary studies. With these studies, the post
post-injection
injection imaging time for
PK11195 was shortened by necessity, due to half
half-life of carbon-11
11 and limited benefit to
extending sessions beyond 60 minutes. Time
Time-activity
activity curves used to analyze whole body
distribution, demonstrated that tumor
tumor-to-background
background ratios did not further improve after
approximately twenty minutes.
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III.

Validation of the Method
Our tumor model was validated. Due to the fact that brain cancers, specifically gliomas

and astrocytomas, have been characterized as overexpressing PBR, glial cell lines were reviewed
to select a model. After consideration, the 9L line was selected. It is utilized in the lab of a
collaborator and known to grow outside the CNS. With this tumor line, we used the previous
studies as a template with the goal of validating the methodology.
For this study, mice were imaged on two sequential days with [18F]FDG and [18F]FLT, for
two hours post injection, with the radiotracer not administered on the first day given on the
second. On the third day, [11C]PK11195 was produced and administered. Mice were imaged for
up to one hour post injection.
In concurrent biodistribution studies, blood, tumor and organs of interest were
collected after an animal has been killed. Ex vivo time-points for all three radiopharmaceuticals
were at 5, 30, and 60 minutes post-injection. For [11C]PK11195, a blocking dose of unlabeled
PK11195 at 5 mg/kg was given at 30 minutes pre-injection to demonstrate specific, ligandmediated uptake.
Results
Biodistribution data is presented in Table 2, and imaging data with 3 tumor-bearing
mice is summarized in Figure 6. The ASIPro (Concorde) analyzed image data are presented as
%ID/cc and SUV. For %ID/cc, regions of interest (ROIs) were drawn on axial slices to quantitate
radiopharmaceutical localization. Data is generated as nCi/cc, and adjusted by correction for
the total amount of activity injected. Standard uptake value, SUV, is used to normalize data to
body size and provides a useful evaluation tool for uptake.
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An SUV of 1 would equal

homogenous distribution or no distinguishable uptake over background. Therefore, an SUV of
less than one would indicate poor localization and greater than one would indicate that the
tumor could be targeted. SUV is calculated by multiplying the %ID/cc by the mass of the
subject.
Table 2a: Biodistribution data of tumor uptake in 9L xenograft (%ID/g) for [18F]FDG, [18F]FLT
and [11C]PK11195.
Radiopharmaceutical
FDG
%ID/g
FLT
%ID/g
PK11195
%ID/g

5 minutes

30 minutes

30 minutes
(+ block)

60 minutes

4.01±0.74

2.39±0.39

NA

3.11±0.79

6.64±0.89

9.09±0.68

NA

7.03±1.15

1.52±0.52

2.70±1.84

2.97±0.78

3.50±0.92

Table 2b: Biodistribution data of tumor uptake in 9L xenografts (%ID/ tumor) for [18F]FDG,
[18F]FLT and [11C]PK11195.
Radiopharmaceutical
FDG
%ID/tumor
FLT
%ID/tumor
PK11195
%ID/tumor

5 minutes

30 minutes

30 minutes
block

60 minutes

0.90±0.51

0.47±0.51

NA

0.64±0.12

2.07±1.037

3.02±0.84

NA

2.49±1.34

0.40±0.31

0.99±0.88

0.73±0.40

1.57±1.10

The FDG data from the ex vivo biodistribution analysis show rapid tumor localization and
provide an example of metabolic variation within tumors. However, due to the location and
growth of the tumors, the [18F]FDG in vivo data is higher than tumor localization ex vivo. Tumors
cells were implanted subcutaneously at the nape, the typical site for our imaging studies of this
tumor line. Unfortunately for these studies, the tumors grew upward towards and onto the skull
to varying degrees. The normal brain uptake of [18F]FDG is high due to the tissue metabolism
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and is the reason for the continued increase of radiopharmaceutical and the extent of
localization for in vivo data. The proximity of the tumor to the brain resulted in significant
spillover from adjacent tissue. This spillover effect is responsible for the lack of correlation
between in vivo and ex vivo data because the ex vivo analysis allows for clear delineation of
tumor versus brain.
A.
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Figure 6: MicroPET time-activity curves for 3 mice with 9L tumors implanted at the nape and
imaged with (A) [18F]FDG, (B) [18F]FLT, and (C) [11C]PK11195. SUV (left) and %ID/cc (right)
values are displayed. Regions of interest were drawn on the axial plane images in ASIPRO to
quantify tumor localization of radioligand.
For [18F]FLT, ex vivo data demonstrates good tumor localization with a peak at the 30
minutes (9.10±0.68 %ID/g), and slight washout at 60 minutes (7.03±1.15). The data from the
images provides a similar trend, with uptake increasing to approximately twenty minutes (4.5%
ID/cc), then stabilizing.
[11C]PK11195 has a moderate increase in uptake at one hour compared to earlier points
(3.50±1.10 at 60 minutes vs. 1.52±0.52, 5 minutes and 2.70±1.84, 30 minutes) and the greatest
variation within each group ex vivo. The trend is seen in the in vivo data as each mouse has
distinct uptake pattern. However, [11C]PK11195 tumor localization was determined to be poor
by SUV (less than 0.5).
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Figure 7: Ex vivo data comparing the distribution of [11C]PK11195 at 30 minutes post-injection
and 30 minutes post-injection with blocking dose. [11C]PK11195 was co-injected with cold
PK11195 at 5 mg/kg. Blocking is seen in organs that express PBR such as the lungs and heart.
Tumor uptake in not altered by the blocking dose suggesting that uptake is non-specific.
In Figure 7, the ex vivo data for 30 minutes (grey bars) and 30 minutes with a blocking
dose of 5 mg/kg (excess) PK11195 are shown. The 9L tumor uptake is not altered by the block
administration; however, the adrenals (positive control organs for PBR) increase in tracer
localization with the block. Tissues that are considered to have moderate expression, such as
the lung, kidney and heart display reduced uptake, as do low expressing tissues. The adrenals
are known to have a high density of receptors, determined to have Bmax values as high as 20,000
fmol/mg protein in rat adrenal tissue.18 Therefore, as radioligand is blocked from other organs,
the adrenal can still bind additional ligand.
Summary of Part III
[11C]PK11195 is not blocked in tumor tissues, nor is uptake of the ligand higher than
other tissues. The time-activity curves do confirm that PK11195 imaging session can be limited
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to one hour after injection without loss of meaningful data, and that data taken at 20 minutes
post-injection is characteristic of the localization of [11C]PK11195 in tumors. The time-activity
curves for [18F]FLT validate our conditions for these tracers as well. However, the site of
implantation for tumor model selected presented a challenge for [18F]FDG validation, and the in
vivo tumor data cannot be separated from the adjacent brain activity.
IV.

Comparison of PK11195 to FEDAA1106
Having demonstrated that our PET methodology for characterization of PBR expression

is valid, the limitations of PK11195 are also evident. As it is the established ligand for PBR due to
the lack of species variations in affinity characteristic of Ro5-4864 and was a prominent tool in
the understanding of PBR, it was a reasonable choice for initial investigations. However the halflife of [11C]PK11195 limits its utility in PET. Fortunately, many alternative PBR ligands have been
developed based on SAR analyses of PK11195 and Ro5-4864. So there are available lead
compounds, a diverse group of structures which have high affinity values and selectivity for
binding to PBR.
Of these, [18F]FEDAA1106 is a particularly promising radiopharmaceutical for targeting
PBR. With the generous assistance of Dr. Robert Mach, Dr. Zhude Tu and Shihong Li, we
compared [11C]PK11195 to [18F]FEDAA1106 in tumor-bearing mice.
Study Design
For the study, three cell lines were implanted in nude mice. The 9L glioma cell line was
selected as well as two human breast cancer cell lines (MDA-MB-231 clones) due to their
overexpression of PBR. In our experience, the MDA-MB-231 tumor line displays drastically
different in vivo growth depending on the cell culture conditions. When the MDA-MB-231 cell
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line available for purchase from ATCC (Manassas, VA) was cultured in CO2-free incubators,
transplanted tumors grew slowly in nude mice. When this cell line was maintained in a 5% CO2
incubator, the transplanted cells developed more quickly into tumors. A second cell line clone
was MDA-BGL2. This cell line was selected by techniques for metastatic potential and was used
with the permission of Dr. Kathy Weilbaecher at Washington University.
(R)-N-desmethyl PK11195 (ABX GmbH, Germany) is methylated by [11C]CH3I produced
on the GE PETtrace MeI MicroLab in a method based on Camsonne et al. Substrate was
dissolved in DMSO with 15% KOH added prior to [11C]CH3I delivery. After [11C]CH3I has been
trapped, the reaction mixture is heated at 90°C (3 minutes). Reverse phase HPLC preparative
separation is used with ACN/ ammonium formate buffer mobile phase.

Product was

reformulated in 10% ethanol in normal saline. Overall synthesis time is 60 minutes from the end
of bombardment, and batch yields were 0.37 to 0.74 GBq (10-20 mCi) with radiochemical purity
greater than 99% and specific activity exceeding 50 TBq/mmol (1,350 Ci/mmol).
N-(5-fluoro-2-phenoxyphenyl)-N-(2-tosylethyl-5-methoxybenzyl),

synthesized

by

Shihong Li and Zhude Tu, is dissolved in DMSO and fluorinated by [18F]fluoride produced by the
18

O(p,n)18F reaction through proton irradiation of enriched 18O water to produce N-(5-fluoro-2-

phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl). Overall synthesis time is 60 minutes,
and had radiochemical purity greater than 99% and specific activity exceeding 54 TBq/mmol
(1,450 Ci/mmol).
Tumor-bearing mice were imaged on two sequential days, receiving one
radiopharmaceutical each day. MDA-BGL2 tumor-bearing mice were imaged on the first day
with [11C]PK11195, and imaged on the next day with [18F]FEDAA1106. For quantification of
localization, biodistribution was performed. Ex vivo analysis compared the distribution of
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radiopharmaceutical at 30 minutes to a blocking group also at 30 minutes. The 9L tumorbearing mice were used for a blocking dose response study to look at the 30 minute time-point
with [11C]PK11195. For [18F]FEDAA1106, the 9L tumor-bearing mice were used to observe the
localization and washout of the radiotracer using 5, 30, and 60 minute time points.
Results
The studies were designed to address several aspects of PBR ligand localization. The
first question asked was: could we see a dose response in [11C]PK11195 uptake with increasing
block? To answer that 9L tumor-bearing mice were given cold PK11195 at concentrations of 1,
5, and 10 mg/kg and groups were compared at 30 minutes post injection ex vivo. In Figure 8,
the data shows that there is a reduction in localization to moderate PBR expressing organs such
as lung and heart. Tumor uptake is not altered by any quantity of excess PK11195. Adrenals do
not block, rather increased uptake of [11C]PK11195 is seen.

35
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% ID/g

25
20
15
10
5
0

30 min

30 min block 1mg/kg

30 min block 5 mg/kg

30 min block 10 mg/kg

Figure 8: Dose Response Blocking study ex vivo with [11C]PK11195. Block doses were
administered 30 minutes prior to radiopharmaceutical, at doses of 1 mg/kg, 5 mg/kg and 10
mg/kg cold PK11195. 9L Tumor-bearing mice were killed 30 minutes post-injection. There is a
dose response in PBR expressing organs, with reduction in lung, kidney and heart. The tumor
uptake does not decrease with increasing unlabeled PK11195.
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Our previous data indicate that [11C]PK11195 will not be a useful ligand for peripheral
tumor imaging. [18F]FEDAA1106 distribution was also assessed in vivo and ex vivo. In Figures 9,
10 and 11, the distribution profile of [18F]FEDAA1106 is shown. Figure 9 illustrates results of ex
vivo analysis of MDA-MB-231 tumor-bearing mice at 30 minutes post-injection and compares
[18F]FEDAA1106 and [11C]PK11195, including brain. Figure 10 shows ASIPro projection of the
summed images for MDA-BGL2 tumor bearing mice administered [11C]PK11195 and
[18F]FEDAA1106. In Figure 11, the distribution of [18F]FEDAA1106 at 5,30 and 60 minutes is
shown. The profile is distinct from that of [11C]PK11195 (Figure 9). Lung uptake is higher for
[18F]FEDAA1106, washing out slowly, and heart has the second highest localization. Adrenal
uptake is lower for [18F]FEDAA1106 than for [11C]PK11195. Kidney and spleen are also organs
with substantial uptake.
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Figure 9: Direct comparison ex vivo PBR ligands distribution in MDA-MB-231 tumor-bearing
mice at 30 minutes post injection. The two PBR ligands possess distinct localization patterns.
FEDAA1106 predominantly localizes the lung, in greater quantities than PK11195. PK11195
has a more homogenous distribution. FEDAA1106 also crosses the blood-brain barrier more
than PK11195, increasing approximately three-fold in uptake at 30 minutes post-injection.
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Figure 10: 9L tumor-bearing
bearing mice ASIPro summed projection images with (A) [11C]PK11195 and
[18F]FEDAA1106.. When PK11195 is administered there is homogenous distribution in the
torso with increased localization in the kidneys. FEDAA1106 has a distinct distribution, with
the greatest uptake in lung and kidney can be visualized in summed two hour scan shown
above.
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Figure 11: Ex vivo data comparing the distribution of [18F]FEDAA1106
106 at 5,30, and 60 minutes
post-injection in 9L tumor--bearing mice. Lung uptake predominates and slowly washes out, to
approximately half of the initial uptake at 60 minutes. Adrenal, heart and kidney have similar
localization at all time points.
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A blocking study was performed using excess PK11195 at 5 mg/kg (Figure 12). One
group was given a blocking dose of excess cold PK11195 (5 mg/kg) at 30 minutes prior to the
injection of the radiopharmaceutical [18F]FEDAA1106. Mice were killed 30 minutes after the
radioactivity was given for ex vivo analysis.

A large reduction of lung localization by

[18F]FEDAA1106 occurred when the animals were given cold PK11195. Heart uptake was slightly
reduced, and adrenal had an increase in radiotracer.
These observations led us to perform a second dose-response study in non-tumor
bearing mice. In this study cold, excess FEDAA1106 was co-administered with [18F]FEDAA1106
at 100 μg/kg, 1 mg/kg, and 10 mg/kg. Data from this study is shown in Figure 13, plotting tissue
versus %ID/g, and Figure 14, plotting %ID/organ versus tissue.

We see a dose-dependent

decrease in lung uptake, with a >50% reduction with 1 mg/kg and >80% reduction with 10
mg/kg. The heart does not decrease with doses of 100 μg or 1 mg/kg, indicating that lung
uptake during oxygenation of blood was the limiting factor in heart uptake, which would be the
next major organ for uptake.
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Figure 12: Blocking study with PK11195 to measure [18F]FEDAA1106 localization 30 minutes
post injection in MDA-BGL2 tumor bearing mice. The largest difference is seen in the lung
with 60% block of [18F]FEDAA1106 localization with a 5 mg/kg unlabeled PK11195 dose.
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Figure 13: Blocking dose response curve (% ID/ g) for non-tumor bearing mice with
[18F]FEDAA1106 with coadministration of cold FEDAA1106. Mice were killed at 30 minutes
post-injection. Lung decrease in [18F]FEDAA1106 localization is dose-dependent. Blocking is
also seen in heart at the unlabeled dose of 10 mg/kg.
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Figure 14: Blocking dose response curve (% ID/ organ) for non-tumor bearing mice with
[18F]FEDAA1106 co-injected with unlabeled FEDAA1106. Mice were killed at 30 minutes postinjection. Lung localization decreases by 23% with 0.1 mg/kg and 65% when 1 mg/kg is given.
When 10 mg/kg is administered the specific localization is blocked and uptake has been
significantly reduced (88% block).
The localization within lung was demonstrated to be receptor-specific by the capacity of
cold PK11195 and FEDAA1106 to prevent uptake in a dose-specific fashion. To satisfy ourselves,
the blocking data was analyzed to account for PBR binding sites. Using reported values for PBR
expression in lung and protein levels in lung tissue, we estimate a total quantity of 47.3
picomoles of PBR in the mouse lung.18,19 By injecting 100 µg/kg of FEDAA1106 we were
administering 5.4 picomoles total dose of FEDAA1106 and a limited reduction of 23% was seen.
With the 1 mg/kg dose of cold FEDAA1106 there was a total of 54 picomoles of receptor
antagonist given, and this resulted in a further decrease in [18F]FEDAA1106 localization to 8.50%
ID/organ. A 10 mg/kg (540 picomoles) injection of FEDAA1106 reduced the radiopharmaceutical
localization by 88% (2.66%). This low level of [18F]FEDAA1106 uptake which can be attributed to
non-specific binding by lipophilic FEDAA1106 (logP=3.7).20
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Figure 14 illustrates two significant findings. The first is that in vivo localization of
[18F]FEDAA1106 predominates in the lungs, an organ rich in PBR. The second important finding
is that the in vivo localization to the lung bed can be prevented by administering excess
FEDAA1106 in a dose dependent manner. When sufficient FEDAA1106 is given to fully occupy
the number of PBR receptor sites in the lungs, localization of the radioligand is negligible. Taken
together, these results indicate that [18F]FEDAA1106 localization to the lung is receptor-specific.
This conclusion has major implications in the use of radiolabeled PBR ligands as
radiopharmaceuticals in tumor imaging.

Summary of Part IV
Comparing the distribution of [11C]PK11195 to [18F]FEDAA1106, we observe a
distribution in which with the lungs retain a large amount of the injected radiopharmaceutical.
Because the lungs are the first major PBR containing organ intraveneously administered
radiolabeled PBR ligands encounter, the lungs act as a reservoir that prevents distribution of
radiopharmaceutical to tissues downstream. The data from the dose-response study with
excess FEDAA1106 proves that the utility of PBR as a target for PET imaging is limited. Ligands
with improved affinity will not provide peripheral tumor localization due to expression of PBR in
lung beds.

Chapter summary
PET provides a method to non-invasively analyze tumors for characteristics such as
metabolism and proliferation. Its strength lies in the potential for longitudinal imaging of
tumors such as initial and follow-up scans to assess changes in tumor properties. It also allows
for multiple tracers to be used as biomarkers to tease out distinct tumor features. We wanted
to compare tumor localization of [18F]FDG, [18F]FLT and [11C]PK11195 in the same animals to
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determine the viability of measuring glucose, proliferation by Thymidine Kinase 1, and
proliferation by PBR, respectively.
In this chapter, the radioligand distributions in vivo and ex vivo were compared. We
previously observed that breast cancer cell lines displayed differential levels of [11C]PK11195
uptake in vitro and characterized cell lines. To build on these findings, tumors were implanted
from these breast cancer cell lines and studied using [18F]FDG, [18F]FLT, and [11C]PK11195.
Imaging data was compared to ex vivo biodistribution measurements. In preliminary studies, we
found similar tumor localization of FDG and FLT, and good tumor localization for PK11195.
These investigations confirmed some expectations and revealed disappointments in
others. As expected, tumors that established quickly with implantation of cells showed a
greater glucose utilization rate as measured with [18F]FDG than cell lines that developed into
solid tumors more slowly. Tumors that took longer to establish their microenvironment had
increasing uptake of [18F]FLT. Despite the observed in vitro differences between cell lines in PBR
expression, the results of in vivo studies were disappointing, with similar low uptake in tumors
regardless of level of PBR.
The results forced us to reevaluate the methods employed. Since PBR has been
investigated in glioma models more extensively, we selected a glioma cell line that was utilized
in the lab of a collaborator for a study to validate the technique. In the study comparing the 9L
tumor line with [18F]FDG, [18F]FLT and [11C]PK11195, we implanted cells in the nape of the neck,
following the standard practice for imaging studies with 9L. This proved to be problematic for
the [18F]FDG data, as tumor grew towards the high background brain tissue. In vivo data
therefore had large spillover activity that resulted in inconsistency between the ex vivo and in
vivo imaging data. The in vivo and ex vivo data for [18F]FLT was in agreement. SUV data
indicates an above background uptake of [18F]FLT in the tumors and they could be visualized.
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[11C]PK11195 data correlates, but the relative uptake compared to [18F]FLT and [18F]FDG was
poor, as was the calculated SUV time activity curve. Additionally, excess cold PK11195 was not
able to block tumor uptake of [11C]PK11195. Other organs known to express PBR were blocked
by the excess compound, such as lung and heart, indicating little specific uptake of the
radiopharmaceutical in the tumor.
The studies performed, taken together, demonstrate poor tumor localization of the PBR
ligand, [11C]PK11195. This compound has been used extensively since its identification in 1983
as a specific ligand for PBR.21,22 In the intervening years, as applications for PET imaging of PBR
have developed, so have additional ligands that display improved affinity values. One is
[18F]FEDAA1106, and this compound was made by collaborators.
We designed studies to evaluate the distribution of [18F]FEDAA1106 and compare the
distribution profile to that of [11C]PK11195. Our data found that the most uptake was seen in
the lungs, and this uptake was significantly increased compared to PK11195. In a dose-response
study with cold FEDAA1106, lung uptake decreased as the dose increased. Heart remains
consistent at low blocking doses, blocked only at the maximum dose of unlabeled FEDAA1106
(10 mg/kg). Adrenal uptake is not affected at low doses and slightly increased at 10 mg/kg.
Taken together, these observations suggest that increasing the affinity for PBR is not useful in
targeting to tumors. Additionally, it suggests that the expression of the protein in the lungs
results in a dramatic decrease in the bioavailability of the radioligand for tumor localization.
Peripheral tumor visualization of PBR by PET imaging of PBR ligands thus holds little promise.
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Chapter 4
Conclusions and Future Directions
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Conclusions
This dissertation presents the results of studies undertaken to characterize peripheral
benzodiazepine receptors (PBR) in breast cancer cell lines in vitro and in vivo. Literature
suggests that the protein holds promise as a biomarker for a range of diseases including cancers
and neuroinflammatory disorders, and as such has been a target for development of novel PET
radiopharmaceuticals in the last decade. However, prior to our beginning this work, research
had focused on the central nervous system, with studies of PBR expression in peripheral disease
states limited to in vitro studies. The desired endpoint of this research was the application of
imaging technology of PET for non-invasive measurement of PBR expression in peripheral
tumors.
In Chapter 2, breast cancer cell lines were characterized. PBR expression was the first
cellular property that was addressed. Our initial plan was to measure and quantify PBR with
Western blot analysis. However, lack of detectable bands in loaded samples and significant nonspecific background signals hampered the utility of this method. Indirect and direct ELISA were
attempted next. For the indirect ELISA, the low absorbance values resulted in a limited capacity
to measure protein levels below a concentration of 10 pmoles/mg total protein. A positive
control cell line that is considered to be a high expressing cell line has a density estimated to be
at this level. Therefore this method could quantify a range of PBR expression. In the direct or
“sandwich” ELISA, the signal was detectable but did not vary across a standards curve. The issue
was identified as cross-reactivity between the primary antibodies, and thus this method could
not be applied. PBR measurements could be assessed using the uptake of [11C]PK11195 in
whole cell studies, and the data show that breast cancer cell lines have differing levels of PBR.

88

The second element of focus was the proliferation potential measured as population
doubling time. To measure this value, cells were counted by hemocytometer at 24 hour
intervals to create a growth curve and calculate PDT. Due to the low number of cells being
counted during early log-phase growth, the accuracy of this method is less than at ideal cell
numbers per 1 mm2 on the hemocytometer. The MTS assay was selected for this purpose. It
does have the disadvantage of a narrow range of quantitative use, but that overlapped logphase growth in these studies so the method was applied. The cells were measured to have
population doubling times that varied from 14 to 40 hours.
Cell aggression was also measured using the “wound-healing” assay and the soft agar
assay. In the “wound-healing” assay, cell migration into the “wound tract” was measured. In
the soft agar assay, the growth capacity of cells in an anchorage-independent environment is
determined. The cell lines analyzed displayed varied capacities to migrate and establish colonies.
The data were compared to determine if there was a correlation between the
expression of PBR and either proliferation or aggression in vitro. There was no correlation seen
between PBR and proliferation. There was a positive correlation for PBR and aggression; both
“wound-healing” and number of cell colonies increased when the cell line displayed higher
levels of PBR.

These data are consistent with literature and indicate that peripheral

benzodiazepine receptor expression could provide a useful biomarker in tumor characterization
in vivo.
In Chapter 3, the potential of PET for in vivo detection and characterization of breast
cancer tumors was explored. In our initial studies, the tumor-bearing mice were imaged with
[18F]FDG, [18F]FLT and [11C]PK11195.

Each animal was imaged with one of the

radiopharmaceuticals and immediately killed for ex vivo biodistribution to quantify uptake of the
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tracer in the xenograft. It was found in the in vivo images and the ex vivo data that each of the
radiopharmaceuticals localized to the tumor.
For more detailed PET studies, the breast cancer cell lines were chosen to select
differential PBR expression, based on our in vitro data from Chapter 2. The goal of this selection
was to determine whether we could observe image contrast with [11C]PK11195, as well as any
correlation with [18F]FDG or [18F]FLT localization to the tumor. Unfortunately, [11C]PK11195
displayed poor tumor uptake, regardless of the in vitro expression of PBR. It was observed that
there was the expected trend of elevated uptake of [18F]FDG in tumors which grew more rapidly,
and that tumors with more established microenvironments have greater uptake of [18F]FLT .
The lack of significant tumor uptake of [11C]PK11195 called to question our methods. To
address the issue, we applied our study parameters to a validated brain tumor model. We
selected a glioma cell line (9L) which is used in the lab of a collaborator and matched their
conditions when employing the cells.

In 9L tumor-bearing mice, [18F]FDG, [18F]FLT , and

[11C]PK11195 were sequentially imaged. Ex vivo biodistribution was performed to quantify
tracer distribution and compare to in vivo data by image analysis. The location of the xenograft
at the nape resulted in confounding results for the [18F]FDG data. Due to tumor growth onto the
skull, and therefore proximity to high glucose consuming brain tissue, there was a large amount
of spillover into the tumor ROI. This resulted in an image artifact that resulted in a PET
overestimation of tumor [18F]FDG uptake that exceeded ex vivo data.

For [18F]FLT and

[11C]PK11195, the uptake of tracer in brain was not a concern, and showed close agreement
between the in vivo and ex vivo data.
These data on [11C]PK11195 indicated that the radiopharmaceutical would not be useful
for detection of PBR on peripheral tumors. However, novel ligands have been designed in
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recent years with improved affinity for PBR, and we compared one of these, [18F]FEDAA1106,
against [11C]PK11195 in studies with 9L and MDA-MB-231 (a PBR positive control breast cancer
cell line).

The biodistribution differed significantly for the two PBR-binding radioligands.

[18F]FEDAA1106 had predominant lung uptake that was demonstrated to be due to specific
binding to PBR in studies with competitive binding with unlabeled PK11195 and in receptor
saturation studies with increasing doses of unlabeled FEDAA1106. From this we conclude that
PBR has limited potential as a PET biomarker of peripheral tumor sites. The high concentration
of PBR in the lungs, limits the amount of intravenously-injected radioligand that reaches PBR
sites in the periphery, including those targeted tumors.
Despite these disappointing results, these data are nonetheless exciting in that they
suggest unexpected new opportunities for research and development of PBR ligands as PET
radiopharmaceuticals. The very high localization of PBR-binding radioligands within the lung
compartment makes them obvious candidates for evaluation as potential radiopharmaceuticals
for PET study of pulmonary disease. PBR numbers are altered in interstitial lung disease, and
PBR ligands have therapeutic effects in pulmonary inflammatory processes. Receptors in the
lung may mediate the inhibition of various airway responses, such as smooth muscle
contraction, microvascular leakage, brochospasm and cough. Because such responses are
common in respiratory diseases like asthma, evaluation of pathological changes in PBR may
identify targets for drug development. Optimization of PET methodologies that noninvasively
measure PBR binding in vivo would thus be useful for not only for increased understanding of
lung pathology, but also for longitudinal studies that evaluate drug and other therapeutic
interventions to improve lung function.
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